{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:08Z","timestamp":1792517948303,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 AG072122"],"award-info":[{"award-number":["U24 AG072122"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tjpad.2025.100102","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T15:46:21Z","timestamp":1740498381000},"page":"100102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4469-6962","authenticated-orcid":false,"given":"Jurij","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjpad.2025.100102_bib0001","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8 Suppl","key":"10.1016\/j.tjpad.2025.100102_bib0002","first-page":"S177","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am J Manag Care"},{"issue":"10468","key":"10.1016\/j.tjpad.2025.100102_bib0003","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","article-title":"Passive anti-amyloid beta immunotherapy in Alzheimer's disease-opportunities and challenges","volume":"404","author":"Heneka","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100102_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100102_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100102_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100102_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100102_bib0008","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100102_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100102_bib0010","doi-asserted-by":"crossref","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","article-title":"beta-amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory Clinic population","volume":"99","author":"Rosenberg","year":"2022","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100102_bib0011","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/jgs.17390","article-title":"Real world\" eligibility for aducanumab","volume":"69","author":"Canevelli","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100102_bib0012","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1007\/s00415-024-12221-7","article-title":"Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort","volume":"271","author":"Canu","year":"2024","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100102_bib0013","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jgs.17530","article-title":"\"Real-world\" eligibility for aducanumab depends on clinical setting and patients' journey","volume":"70","author":"Padovani","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100102_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5789","article-title":"Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-utilising cerebrospinal fluid biomarkers and appropriate use criteria","volume":"37","author":"Togher","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100102_bib0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.2023.166","article-title":"Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK","volume":"224","author":"Laurell","year":"2024","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100102_bib0016","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","article-title":"The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set","volume":"21","author":"Beekly","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100102_bib0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.wad.0000213865.09806.92","article-title":"The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers","volume":"20","author":"Morris","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100102_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WAD.0b013e318191c7dd","article-title":"The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery","volume":"23","author":"Weintraub","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100102_bib0019","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WAD.0000000000000279","article-title":"Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set","volume":"32","author":"Besser","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100102_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100102_bib0021","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100102_bib0022","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100102_bib0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100102_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100102_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [(11)C]PIB-PET centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100102_bib0026","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","article-title":"Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition","volume":"136","author":"Thal","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100102_bib0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","article-title":"Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease","volume":"9","author":"Salloway","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100102_bib0028","series-title":"R: a language and environment for statistical computing","year":"2024"},{"issue":"43","key":"10.1016\/j.tjpad.2025.100102_bib0029","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Software"},{"key":"10.1016\/j.tjpad.2025.100102_bib0030","unstructured":"eulerr: area-Proportional Euler and Venn Diagrams with Ellipses. R package version 7.0.0 [Internet]. 2022. https:\/\/CRAN.R-project.org\/package=eulerr."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100102_bib0031","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100102_bib0032","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/NEN.0000000000000016","article-title":"Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center","volume":"72","author":"Serrano-Pozo","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100102_bib0033","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","article-title":"Cognitive differences in dementia patients with autopsy-verified AD, lewy body pathology, or both","volume":"64","author":"Kraybill","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100102_bib0034","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.13028","article-title":"Lewy body pathology in Alzheimer's disease: a clinicopathological prospective study","volume":"139","author":"Savica","year":"2019","journal-title":"Acta Neurol Scand"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:16:02Z","timestamp":1744517762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2274580725000469"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100102","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100102"}}